T-DM1 Significantly Improved Progression-Free Survival In Randomized Phase II Trial

[News]

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine (T-DM1, previously known as trastuzumab-DM1) in HER2-positive metastatic breast cancer (MBC)...

More... (http://www.medicalnewstoday.com/articles/221851.php)